MaxCyte (NASDAQ:MXCT) Shares Gap Down to $6.23

MaxCyte, Inc. (NASDAQ:MXCTGet Rating)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $6.23, but opened at $6.09. MaxCyte shares last traded at $5.99, with a volume of 5,751 shares traded.

Wall Street Analysts Forecast Growth

Separately, BTIG Research lifted their target price on shares of MaxCyte from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Sunday, August 14th.

MaxCyte Stock Up 0.5 %

The company has a 50-day moving average of $5.62. The stock has a market capitalization of $624.38 million, a price-to-earnings ratio of -30.65 and a beta of 1.17.

Insider Transactions at MaxCyte

In other news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of MaxCyte stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $4.30, for a total value of $13,912,856.40. Following the transaction, the insider now directly owns 10,735,786 shares of the company’s stock, valued at $46,163,879.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.11% of the stock is currently owned by insiders.

Institutional Trading of MaxCyte

Several institutional investors have recently made changes to their positions in MXCT. American Century Companies Inc. acquired a new stake in shares of MaxCyte during the first quarter worth approximately $11,583,000. Vitruvian Partners LLP boosted its holdings in shares of MaxCyte by 31.7% during the first quarter. Vitruvian Partners LLP now owns 4,385,670 shares of the company’s stock worth $30,656,000 after purchasing an additional 1,055,670 shares during the period. Millennium Management LLC boosted its holdings in shares of MaxCyte by 67.3% during the second quarter. Millennium Management LLC now owns 2,355,086 shares of the company’s stock worth $11,140,000 after purchasing an additional 947,104 shares during the period. Goldman Sachs Group Inc. lifted its stake in MaxCyte by 317.5% in the first quarter. Goldman Sachs Group Inc. now owns 1,003,738 shares of the company’s stock valued at $7,016,000 after acquiring an additional 763,344 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in MaxCyte by 26.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,367,838 shares of the company’s stock valued at $11,200,000 after acquiring an additional 495,641 shares during the last quarter. 66.40% of the stock is currently owned by institutional investors and hedge funds.

About MaxCyte

(Get Rating)

MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Featured Stories

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.